Objective The standard treatment for submucosal esophageal cancer is esophagectomy or chemoradiotherapy (CRT). However, these treatment modalities could deteriorate the general condition and quality of life of the patients who are intolerant to invasive therapy. It is therefore important and beneficial to develop less invasive treatment protocols for these patients. Methods The study included 43 patients who were clinically suspected of mucosa or submucosal esophageal cancer but underwent endoscopic submucosal dissection (ESD) as a primary treatment, due to the patients' poor performance statuses and/or preferences for less invasive therapy. According to the pathological findings and patient's general condition, whether the patient underwent additional treatments or remained hospitalized without additional treatments was thereafter decided for each patient. We retrospectively analyzed the outcomes of these patients. Results Fifteen patients underwent additional surgery, 11 patients underwent CRT/radiation therapy (RT) and 17 patients were followed without additional treatments. During the 3-year follow-up period, the relapsefree survival rates in the patients who received or did not receive additional treatments were 88% and 64%, respectively (95% confidence interval, 0.45-0.76, p=0.04). The relapse-free and overall survival rates in the patients with additional treatments were equivalent or superior to those described in previous reports of the standard treatments. Preceding ESD contributed to reduce the local relapse significantly to approximately 3.5% and additional CRT-related toxicities. Conclusion Preceding ESD is very effective for the local control of cancer, and useful for histologically confirming the high-risk factors of relapse, such as ! submucosal layer 2 (SM2) invasion and lymphovascular involvements. ESD with additional therapy may be a promising strategy for optimizing the selection of therapy depending on the patient's general condition.
vances in diagnostic modalities, including endoscopy and endoscopic ultrasonography (3) . The majority of gastrointestinal cancers develop in the elderly patients, and esophageal carcinoma is no exception with a median age of 68 years at the diagnosis (2) . Esophagectomy with three-field lymph node dissection is the standard treatment for patients with superficial esophageal carcinoma (4). Igaki et al. reported an 86% 3-year overall survival rate using a retrospective analysis on 57 clinical stage I esophageal SQC patients treated with esophagectomy (5) . However, esophagectomy often deteriorates the patient's general condition, especially in elderly patients. Chemoradiotherapy (CRT) or radiotherapy (RT) has been recognized as a reliable, non-surgical standard treatment for local superficial lesions in the medically inoperable patients or for unresectable advanced lesions. A phase II trial (JCOG9708) was conducted to evaluate the efficacy and the safety of concurrent CRT using 5-fluorouracil (5-FU) plus cisplatin (CDDP) for clinical stage I esophageal SQC (6) . The results of this study demonstrated that CRT showed a complete response rate (87.5%) and 70% 3-year relapse-free survival rate. However, 22% of the patients showed local relapses which required salvage treatments. Furthermore, the association of CRT with a high rate of serious late toxicities, especially to the heart and pleura, were reported (7, 8) . For the patients who have multiple comorbidities, poor performance status, and are elderly, late toxicities after CRT often become a critical fatal issue (9) (10) (11) .
Endoscopic resection, such as endoscopic mucosal resection (EMR) and endoscopic submucosal dissection (ESD), is usually indicated for T1a esophageal cancer, whereas the standard treatment for T1b cancer has been esophagectomy with three-field lymph node dissection as aforementioned because of the high incidence of lymph node metastasis. There was a clear difference in the treatment results depending on the level of tumor invasion; the tumor depth was a significant factor for the overall survival (12) . A recent study revealed the correlation between the rate of lymph node metastasis and the depth of the tumor invasion of superficial esophageal cancers. The rate of lymph node metastasis of the lesions infiltrated into the upper one-third of the submucosa (SM1), the middle one-third (SM2), and the bottom one-third (SM3) were 27%, 36%, and 55%, respectively (13) .
It is often difficult to precisely estimate the levels of tumor invasion and lymphovascular involvements before the standard treatments of surgery and CRT (14) . There have been only a few studies focusing on the outcome of submucosal esophageal cancer treated by endoscopic resection followed by additional treatments (15) (16) (17) .
In this study, we retrospectively analyze the efficacy, safety, and clinical outcomes of the patients who underwent local treatment of submucosal esophageal cancer using preceding ESD with or without additional treatments.
Materials and Methods

Characteristics of the patients
Between January 2005 and December 2010 at the Kobe University hospital, 166 patients were clinically diagnosed with superficial esophageal SQC (T1a-T1b). The depth of tumor invasion was suspected to be to the mucosa (M3) or submucosa (SM) in 43 patients by high-resolution endoscopy with iodine staining, magnified endoscopy with narrow-band imaging (NBI), endoscopic ultrasonography (EUS) and a pathological examination of the biopsy samples. Due to the patient's poor performance status and/or personal preference for avoiding invasive therapy, ESD was selected as a primary treatment instead of standard surgery or CRT. After no signs of lymph node or distant metastasis were confirmed by the chest and abdominal computed tomography (CT) scans, all patients underwent ESD.
All the patient data, such as age, presence of diabetes and/or cardiac disease, previous and concurrent other carcinomas, were collected from the medical records and were classified by the Charlson comorbidity score. Each patient's condition was assigned a score, and the higher score indicates greater comorbidity. Informed consent was obtained from all the patients.
Endoscopic submucosal dissection (ESD)
ESD was performed under conscious sedation by the periodic intravenous administration of midazolam while monitoring the blood pressure, heart rate and blood oxygen saturation. According to the method described in our previous report, ESD was performed by skilled endoscopists using a Flush-Knife (Fujinon, Tokyo, Japan) and electrosurgical generator (VIO300D, ERBE Elektromedizin GmbH, Tubingen, Germany) (17) .
Pathological evaluation
The removed specimens were microscopically examined by at least two or three experienced pathologists and evaluated according to the Japanese Classification of Esophageal Cancer, 10th edition (Japan Esophageal Society). The histological type, depth of invasion, lateral and vertical resection margins, and presence of lymphovascular involvements was determined.
Additional treatment
According to the results of the pathological evaluation of the ESD samples, the patient's condition and their personal preference for therapeutic strategy, whether the patients underwent additional treatments or were observed without additional treatments was then decided. One of treatments listed below (I-IV) was selected according to the doctor's discretion and the patient's preference:
I. Esophagectomy and three-field lymphadenectomy (neck, mediastinum and upper abdominal lymphadenectomy) (OP) was performed within 60 days after ESD.
II. CRT was started within 60 days after endoscopic resection. The details of additional CRT were as follows: CDDP was administered at a dose of 70 mg/m 2 by a slow drip infusion on days 1 and 29. 5-FU was administered at a dose of 700 mg/m 2 /d by a continuous infusion for 24h on days 1-4 and 29-32. The dose of radiotherapy was 41.4 Gy/ 23 Fr/5 weeks (5 days/week) for the cases with a negative endoscopic resection margin and 50.4 Gy/28 Fr/5 weeks (5 days/week) with a boost on the primary site for the cases with a positive resection margin or carcinoma with deeper than SM3 invasion.
III. The patients who were not able to undergo chemotherapy or surgery underwent RT alone under the conditions listed in II.
IV. The patients who were intolerant to further treatment were followed without any additional treatments.
In the cases of relapse after these additional treatments or observations, some patients who were tolerant to further intervention underwent palliative surgery or CRT/RT as salvage therapy.
Follow-up The patients were followed with blood tests, upper gastrointestinal endoscopy and chest and abdominal CT at least every three or four months for three years following ESD. Afterward, the patients were followed with upper gastrointestinal endoscopy and computed tomography every six months. The follow-up data were updated in March 2014.
Evaluation of relapses
Local relapse was defined by a positive biopsy at upper digestive endoscopy. Metastatic relapse (progression) was defined with the appearance of metastatic lesions in the distant organs and/or swelling of the lymph nodes. Toxicity An assessment of the toxicities was in accordance with the Common Terminology Criteria for Adverse Events (CTCAE), ver. 4.0 (18) . Statistics Statistical analysis was performed using the t-test for twoproportion comparisons. The overall survival time was calculated from the date of endoscopic treatment until death or the last follow-up for surviving patients. The relapse-free survival rate was defined as the time from the date of endoscopic treatment to either the record of metastasis, relapse, or death from any cause. The time to progression curve was established using the Kaplan-Meier method and compared with the log-rank test. In all analyses, a p value of less than 0.05 was considered to be statistical significant. All statistical analyses were performed using the STATA software program (STATA for Windows, ver. 11.1, Stata Corp, College Station, USA).
Results
The clinical characteristics of 43 patients and their lesions are presented in Table 1 . The patients included 37 men and 6 women with a median age of 71 years (range 47-88 years). The primary tumor location was as follows: 2 in the cervical or upper thoracic esophagus (4.6%), 22 in the middle thoracic esophagus (51.2%) and 19 in the lower thoracic and abdominal esophagus (44.2%). The European Collaborative Oncology Group (ECOG) performance status of 40 patients (92%) was 0 or 1. The median Charlson comorbidity score was 2 (range 1-10), and five patients (11.6%) had scores over 5. The most frequent major comorbidity was a history of pulmonary conditions. Before ESD, the estimates of the clinical tumor invasion depth were as follows: M3-SM1 in 32 patients (74.4%) and SM2-3 in 11 patients (25.6%). There were no complications with the ESD procedure. Forty tumors (93%) were well or moderately differentiated, and three (7%) were poorly differentiated. The distribution of the depth of tumor invasion in the resected specimens evaluated by the histological examination was as follows: SM1 in 19 patients (44.1%), SM2 in 18 patients (41.8%), and ! SM3 in 6 patients (14.1%). Of 43 carcinomas, lymphovascular involvements were observed in 17 (39.5%). The lateral margins of all resected specimens were free, and the vertical margin was positive in 9 patients (21.0%), which indicated a margin-free complete resection rate of 79%. The accuracy of the diagnostic performance before ESD was 60.4%.
After preceding ESD, 26 patients (60.3%) underwent additional treatments of OP or CRT/RT. Seventeen patients (39.7%) decided to stay without additional therapy due to their poor general condition or personal preference after being informed of the potential risk of metastasis and relapse ( Table 2 ). The median age of the patients who underwent additional treatments was 69 years of age, which was significantly younger than the median age of 77 years of age of the patients who did not receive additional therapy. The rates of massive invasion (! SM2) and pathological lymphovascular involvements with additional treatments were significantly more frequent than in the patients without additional therapy.
Among 26 patients, 15 patients (34.8%) were able to undergo OP, and CRT/RT was performed on 11 patients (25.5%) ( Table 3 ). There was no significant difference in the characteristics between the patients who received additional OP and CRT/RT. Among 15 patients with additional OP, 3 patients had one or more postoperative complications; 2 had pulmonary complications, one anastomotic leakage and one vocal cord palsy. Unfortunately, one patient died of pneumonia and sepsis at 54 days after additional OP (114 days after ESD) (Supplementary material 1). Another patient died due to a surgery-related complication (3.3%), and one patient died of other disease. 13 patients (86.7%) were alive without relapse during the follow-up period of 47 months.
Among 11 patients with additional CRT/RT, 7 patients (63.6%) with a negative endoscopic resection margin underwent a 41.4 Gy dose of radiotherapy and 4 patients (36.4%) with a positive margin or ! SM3 invasion underwent a 50. 4 Gy dose of radiotherapy. Grade 3 leucopenia and esophagitis were observed in one patient (9%). All other complications, such as pneumonia, sepsis, renal failure, liver failure, and radio dermatitis, were not observed (0%). There were no late major treatment toxicities in 11 additional CRT/RT patients, and no treatment-related deaths occurred (Supplementary material 2). During the follow-up period of 43 months, three patients (27.2%) experienced distant relapses of esophageal carcinoma (Table 4) . Of these three, two patients experienced distant lymph nodal relapse at 17 and 43 months, respectively. One patient showed distant lymph nodal relapse and liver metastases at 12 months after ESD. Despite the further salvage treatments, three patients died of esophageal cancer. These three patients were considered to be a high-risk group of relapse due to their tumor massive invasion (! SM2) with lymphovascular involvements. Furthermore, one patient died of other disease.
Seventeen patients were followed without receiving any additional treatments after ESD (Table 5 ). During the follow-up period of 37 months, 6 (35.2%) patients had relapses of esophageal carcinoma (5 lymph nodal relapses and one isolated lung metastasis). Five patients with lymph nodal relapses received salvage CRT/RT, however, one patient died of esophageal cancer. One patient with an isolated lung metastasis underwent segmental lung resection and is currently alive with no evidence of relapse. Two patients died of other diseases. Among all 43 patients, massive invasion (! SM2) with lymphatic involvement was observed in 12 (27.9%). These 12 patients were regarded as the high-risk relapse group because 5 of 12 patients (41.6%) had relapses. Furthermore, among 31 non-high-risk patients, there were only 4 (12.9%) relapses. On the other hand, among 9 patients who had a relapse, massive invasion (! SM2) with lymphatic involvement was observed in 4 cases (44.4%). Among 34 patients without relapse, massive invasion (! SM2) with lymphatic involvement was observed in 9 cases (26.2%).
The relapse-free survival rate of the patients who received additional treatment and those who did not was 88% and 64%, respectively (Table 6) , which was significantly different (95%CI, 0.45-0.76, p=0.04, Fig. 1 ). The relapse-free survival rate of additional OP and CRT/RT were 86% and 69%, respectively. There was no significant difference in the recurrence-free survival rate between additional OP and CRT/RT (95%CI, 1.21-1.62, p=0.21, Fig. 2 ). However, there OP tended to be superior to CRT/RT according to the recurrence-free survival rate.
Among 28 patients who did not receive additional surgery, the local relapse of esophageal cancer only occurred in one patient (3.5%) ( Table 7) . The local relapse rate in the present study was better than those observed in previous reports of standard CRT with stage I esophageal cancer.
Discussion
ESD is now widely performed for superficial esophageal cancer. However, it should be noted that ESD is technically difficult even if the frequency of complications, such as perforation, decreases due to the improvement of devices and techniques (19) (20) (21) . Fortunately, ESD was performed safely in all the patients without serious complications with a good complete resection rate of 79% in this study. We believe that this result is partly attributed to the advanced ESD skills of the endoscopists in this hospital. Therefore, we strongly suggest that ESD should be performed by the doctors who have been trained for ESD with adequate experience.
The incidence of lymph node metastasis for the patients with mucosal invasive carcinoma is low, whereas it is relatively high in those with submucosal invasive carcinoma. Akutsu et al. observed that when the tumor depth was ! SM 2, the patient had both a higher rate of lymph node involvement and also hematological recurrences, such as liver or lung metastases (13) . Furthermore, their univariate and multivariate analyses showed that the tumor depth and presence of lymphatic and venous invasion were identified to be independent risk factors. Igaki et al. reported that 33% of the patients who were clinically diagnosed as lymph node negative before surgery, turned out to be pathologically lymph node positive (5). These results indicate that some patients diagnosed with clinical stage I without lymph node metastases may actually have lymph node metastases. This suggests that treatments regarding lymph node metastasis should be recommended for clinical stage I esophageal cancer; unfortunately, it also suggests that 67% of the patients who are truly lymph node negative may be forced to receive unnecessarily invasive treatment. Therefore, it is very important to know accurately determine the risk of lymph node metastases for each esophageal cancer patient. Among 43 patients in the present study, ! SM2 was evident in 55.9% and lym- phovascular involvements were detected in 39.5% of the patients. The accuracy of the diagnostic performance before ESD was 60.4%, which was lower than previous reports (22) (23) (24) . The reason for the misdiagnosis of many cases in the present study was that the macroscopic appearance of the tumor influenced the tumor depth of invasion; it remains exceedingly difficult to differentiate between mucosal and sub-mucosal lesions. We also found that ! SM2 invasion with lymphatic involvement was observed in 27.9% cases. Relapses appeared later in 41% of the patients in these high-risk groups, which was higher than the rate of non-high-risk patients (12%). Hence, preceding ESD has the advantage of selecting the patients with a high risk of relapse according to the pathological findings, which would help to decide if additional therapy should be recommended. Esophagectomy is currently the standard therapeutic approach for submucosal esophageal cancer, however, the mortality and post-surgical complications are not negligible (25) . Unfortunately, one patient with advanced age and cardiac or pulmonary complications died of pneumonia and sepsis at 54 days in the present study. Such patients have been previously treated with CRT or RT, however, a definitive cure cannot be expected. CRT plays a role in the esophageal cancer treatment through the control of local and distant recurrences and is considered to be one of the more effective modalities for early and advanced esophageal carcinomas (26) . Several multi-institutional studies reported a 2-year local control rate of 70-80% and a 3-year survival rate of 71-83% in superficial esophageal cancers treated with CRT, although 20-22% of the patients had local relapses within the radiation field (26, 27) . These findings of these studies indicate that CRT is less toxic than surgery, but insufficient for the local relapse control. In the present study, 28 patients who did not undergo additional OP showed only 3.5% of local relapse without any death caused by post-ESD complications. This result was better than the rates of previous reports (6, 7) (Table 7) . Moreover, the rate was better than the rate of the Kobe University Hospital study of CRT treatment for clinical stage I esophageal SQC (local relapse rate: 14%, n=21). ESD may also accomplish a high rate of en-bloc resection and R0 resection. This suggests that preceding ESD is not only less invasive but also exceptional for controlling the local relapse.
According to the results of the pathological evaluation, additional treatments should be recommended for the patients who can undergo them. Seventeen patients (39.7%) decided to stay without any additional treatments due to the intolerance for further treatments or preference for minimized physical stress from the medical intervention. The rate of the patients who did not receive any additional treatments was higher than the rate of previous reports of 11-22% (15, 19) . One reason that we observed a higher rate may have been due to the age of the patients; the median age of these 17 patients was significantly older than the patients who received additional therapy. Among 17 patients, 7 patients (41%) were over 80 years of age. The Charlson comorbidity score is a scale that predicts the 1-year mortality for patients who have a range of comorbid conditions, such as heart disease, and it tended to be higher in those patients (28). Anderson et al. reported a correlation between a Charlson comorbidity score of ! 2 and grade 3 or 4 toxicity of CRT (29) . The patient's age, multiple comorbidities, and poor performance status often become critical fatal issues for the patients during and after surgery or CRT/RT. Therefore, it is very important to evaluate the comorbidity carefully when determining the additional treatments (30) (31) (32) (33) .
Acute and late cardiopulmonary toxicity due to CRT is a critical issue (34) (35) (36) and is observed in 2-10% of the patients according to previous reports (6, 7, (8) (9) (10) (11) . To prevent it, not only the improvement of radiation techniques, but also a reduction of the radiation dose to the esophagus, heart and lung are important. Therefore, smaller radiation fields and conformal radiotherapy would be helpful. Ishikura et al. suggested that a reduction in the radiation dose, careful observation, and control the late toxicity may improve the post-CRT survival (37) . In our study, the dose of radiotherapy was reduced to 41.4 Gy in 7 cases (63.6%) with additional CRT, following successful curative endoscopic resection, which was confirmed by the histological evaluation. Acute toxicities of grade! 3 of CRT/RT were observed in 9% of the patients, while late toxicities of grade! 3 were not observed. According to these results, the acute and late toxicities of the patients who underwent additional CRT were equivalent or less severe than the previous reports of standard CRT. Among the 7 patients treated with reduced CRT (41.4 Gy), there was one relapse (14.2%). Among 11 patients with additional CRT, three relapses (27%) were observed. These results were similar to the rate of the previous reports of 25-50% (6, 13) . Therefore, preceding ESD contributed to the reduction of the radiation dose and fields and prevented RT-related toxicities without increasing the relapse rate.
Among 11 patients who underwent additional CRT/RT in this study, there were three distant relapses of esophageal cancer (27.2%). These three had massive invasion (! SM2) with lymphovascular involvements. The rates of ! SM2 invasion and pathological lymphovascular involvements of the patients who received additional treatments were significantly higher than the patients who did not receive additional therapy (Table 2) . However, the three-year relapse-free survival rates of the patients who received additional treatments (88%) were significantly better than the patients who did not receive additional treatments (64%). The three-year relapse-free survival and overall survival rates in the patients who received additional treatment in our study were equivalent or superior to previous reports of patients treated by surgery or CRT/RT (Table 6 ) (5-7). The survival rates in the present study were also better or at least equivalent to the rate observed in the Kobe University Hospital cohort treated by OP or CRT for clinical stage I esophageal SQC (3-year relapse-free survival rate: OP 82.2% n=45, CRT 76.6% n= 21). These results suggest that appropriate additional treatments have the potential to reduce the risks of recurrence (Fig. 1) .
There was no significant difference in the recurrence-free survival between additional OP and CRT/RT. However, additional OP tended to be superior to CRT/RT (Fig. 2) . Thus, for the patients with high relapse risks of tumor massive invasion (! SM2) with lymphovascular involvements, we recommend OP over CRT/RT. However, in the patients who received additional OP, one patient died due to treatmentrelated death. Therefore, for the high-risk relapse patients, additional treatment should be carefully chosen, and the patient's ages and comorbidities must be considered.
Among 17 patients who did not receive additional treatments, six patients (35.2%) had distant relapses of esopha-geal cancer. Unfortunately, this finding was worse than the previous reports of standard treatments of surgery or CRT. Conversely, 5 of the 17 patients (29.4%) who did not receive additional treatment but underwent salvage therapy achieved a long-term survival. Even if the high-risk relapse patients do not wish for additional therapy, careful follow-up and quick salvage treatment could lead to a long-term survival.
There are several limitations associated with the present study. We conducted a retrospective analysis and singlecenter study with a small number of cases. Future studies with a large number of cases and more extended follow-up period are warranted.
In conclusion, preceding ESD with additional therapy may lead to the control of the local relapse of cancer and optimize the selection of therapeutic strategy, which can further minimize the physical stress from treatments. Thus, it may be a beneficial treatment protocol for submucosal esophageal cancer patients, especially those with a poor general condition.
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